secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001493152-24-044930
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra Q3 net loss narrows to $1.0M; pipeline advances with ATR-12 dosing, ATR-04 IND clearance
--------------------------------------------------------------------------------

- Net loss of $1.0M in Q3 2024 vs $1.9M in Q3 2023; cash and equivalents $7.3M as of Sept 30, 2024.
- R&D expenses rose to $1.0M from $0.5M; G&A steady at $1.9M; service revenue was $0 vs $310K.
- Completed $10M follow-on offering; dosed first Netherton syndrome patient with ATR-12 in Phase 1b trial.
- Received IND clearance and Fast Track designation from FDA for ATR-04 to treat EGFRi-associated rash.
- Anticipates initial safety data from ATR-12 trial in Q1 2025; first ATR-04 patient dosed in Q1 2025; topline data YE 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000149315224044930/0001493152-24-044930-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000149315224044930/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-044930

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer